Estados Unidos - inglés - NLM (National Library of Medicine)

heel inc - .alpha.-lipoic acid (unii: 73y7p0k73y) (.alpha.-lipoic acid - unii:73y7p0k73y), avena sativa flowering top (unii: ma9cqj3f7f) (avena sativa flowering top - unii:ma9cqj3f7f), ricinus communis seed (unii: 7ek4sfn1tx) (ricinus communis seed - unii:7ek4sfn1tx), solidago virgaurea flowering top (unii: 5405k23s50) (solidago virgaurea flowering top - unii:5405k23s50), viola tricolor (unii: 9q24rai43v) (viola tricolor - unii:9q24rai43v), berberis vulgaris root bark (unii: 1th8q20j0u) (berberis vulgaris root b - .alpha.-lipoic acid 3 [hp_x] - - fatigue - mild skin rashes - nausea and headaches

Estados Unidos - inglés - NLM (National Library of Medicine)

medinatura inc - .alpha.-lipoic acid (unii: 73y7p0k73y) (.alpha.-lipoic acid - unii:73y7p0k73y), avena sativa flowering top (unii: ma9cqj3f7f) (avena sativa flowering top - unii:ma9cqj3f7f), berberis vulgaris root bark (unii: 1th8q20j0u) (berberis vulgaris root bark - unii:1th8q20j0u), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e), cholesterol (unii: 97c5t2uq7j) (cholesterol - unii:97c5t2uq7j), juglans regia flowering top (unii: 3ba2n709ng) (juglans regia flowering top - unii:3ba2n709ng), strychnos nux-vomi - .alpha.-lipoic acid 3 [hp_x] - cleansing tablets relieves: • fatigue • headache • bloating for the temporary relief of minor fatigue, headache, bloating

Estados Unidos - inglés - NLM (National Library of Medicine)

alembic pharmaceuticals limited - venlafaxine hydrochloride (unii: 7d7rx5a8mo) (venlafaxine - unii:grz5rcb1qg) - venlafaxine 25 mg - venlafaxine tablets are indicated for the treatment of major depressive disorder.    the efficacy of venlafaxine tablets in the treatment of major depressive disorder was established in 6-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the dsm-iii or dsm-iii-r category of major depression and in a 4-week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia (see clinical trials ).   a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the effica

Estados Unidos - inglés - NLM (National Library of Medicine)

aspen veterinary resources, ltd. - .alpha.-tocopherol, d- (unii: n9pr3490h9) (.alpha.-tocopherol, d- - unii:n9pr3490h9), vitamin a (unii: 81g40h8b0t) (vitamin a - unii:81g40h8b0t), vitamin d (unii: 9vu1ki44gp) (cholecalciferol - unii:1c6v77qf41) - .alpha.-tocopherol, d- 201 mg in 1 ml - natural e-ad (vitamin a, d3 , and e) injectable d-alpha-tocopherol with ad not for use in humans keep out of reach of children natural vitamin a (carotenes), and tocopherols can be destroyed in feedstuffs through processing, ensiling and storage. due to these losses, reduced intakes of fat-soluble vitamins can occur in animals maintained in continual confinement compared to animals allowed to graze in lush pasture. intramuscular or subcutaneous injections offer an efficient and rapid method to increase vitamin a, vitamin d and vitamin e status of animals. indications vita-jec essential e-ad injectable d-alpha-tocopherol with ad is clear, sterile, water emulsifiable solution of vitamin a, vitamin d3 , and vitamin e. this product is intended as a supplemental source of natural vitamins a, d, and e. 

Estados Unidos - inglés - NLM (National Library of Medicine)

cadila pharmaceuticals limited - venlafaxine hydrochloride (unii: 7d7rx5a8mo) (venlafaxine - unii:grz5rcb1qg) - venlafaxine tablets are indicated for the treatment of major depressive disorder. the efficacy of venlafaxine tablets in the treatment of major depressive disorder was established in 6 week controlled trials of adult outpatients whose diagnoses corresponded most closely to the dsm-iii or dsm-iii-r category of major depression and in a 4 week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia (see clinical trials ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the efficacy of venlafaxine hydrochloride extended-release capsules in maintaining an antidepressant response for up to 26 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial. the efficacy of venlafaxine tablets in maintaining an antidepressant response in patients with recurrent depression who had responded and continued to be improved during an initial 26 weeks of treatment and were then followed for a period of up to 52 weeks was demonstrated in a second placebo-controlled trial (seeclinical trials ). nevertheless, the physician who elects to use venlafaxine tablets/venlafaxine hydrochloride extended-release capsules for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. hypersensitivity to venlafaxine hydrochloride or to any excipients in the formulation the use of maois intended to treat psychiatric disorders with venlafaxine hydrochloride or within 7 days of stopping treatment with venlafaxine hydrochloride is contraindicated because of an increased risk of serotonin syndrome. the use of venlafaxine hydrochloride within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see warnings and dosage and administration ). starting venlafaxine hydrochloride in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see warnings and dosage and administration ). venlafaxine hydrochloride is not a controlled substance. in vitro studies revealed that venlafaxine has virtually no affinity for opiate, benzodiazepine, phencyclidine (pcp), or n-methyl-d- aspartic acid (nmda) receptors. venlafaxine was not found to have any significant cns stimulant activity in rodents. in primate drug discrimination studies, venlafaxine showed no significant stimulant or depressant abuse liability. discontinuation effects have been reported in patients receiving venlafaxine (seedosage and administration ). while venlafaxine hydrochloride has not been systematically studied in clinical trials for its potential for abuse, there was no indication of drug-seeking behavior in the clinical trials. however, it is not possible to predict on the basis of premarketing experience the extent to which a cns active drug will be misused, diverted, and/or abused once marketed. consequently, physicians should carefully evaluate patients for history of drug abuse and follow such patients closely, observing them for signs of misuse or abuse of venlafaxine hydrochloride (e.g., development of tolerance, incrementation of dose, drug-seeking behavior).

Australia - inglés - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - tadalafil, quantity: 20 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; colloidal anhydrous silica; povidone; poloxamer; croscarmellose sodium; sodium lauryl sulfate; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow - tadalafil alphapharm is indicated for the treatment of:,? erectile dysfunction (ed) in adult males,? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Australia - inglés - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - tadalafil, quantity: 5 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; povidone; microcrystalline cellulose; sodium lauryl sulfate; poloxamer; colloidal anhydrous silica; lactose; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow - tadalafil alphapharm is indicated for the treatment of:,? erectile dysfunction (ed) in adult males,? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Australia - inglés - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - tadalafil, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; sodium lauryl sulfate; colloidal anhydrous silica; povidone; poloxamer; lactose; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow - tadalafil alphapharm is indicated for the treatment of:,? erectile dysfunction (ed) in adult males,? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

pacific pharmaceuticals limited (part of mylan) - hydralazine hydrochloride 25mg - tablet - 25 mg - active: hydralazine hydrochloride 25mg excipient: colloidal silicon dioxide disodium edetate dihydrate magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc sodium starch glycolate

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

pacific pharmaceuticals limited (part of mylan) - hydralazine hydrochloride 50mg - tablet - 50 mg - active: hydralazine hydrochloride 50mg excipient: colloidal silicon dioxide disodium edetate dihydrate magnesium stearate microcrystalline cellulose opadry pregelatinised maize starch purified talc purified water sodium starch glycolate